Black Diamond Therapeutics shares are trading higher after the company was granted Fast Track designation by the FDA for BDTX-189 for treatment of adult patients with a solid tumor harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20 Insertion UPDATE: Shares have since reversed, now lower.